Koninklijke Philips (PHIA) CMD 2026 summary

Strategic direction and growth ambitions

• Targeting mid-single-digit sales CAGR and mid-teens margins by 2028, aiming to improve 2.5 billion lives by 2030 and embedding sustainability in business models.

• Three-pillar strategy: focused value creation by segment, innovation growth leveraging AI and data, and disciplined execution with commercial excellence.

• Transitioned from a 70/30 growth/margin strategy to segment-specific strategies, targeting growth and margin expansion in all business units.

• North America identified as the primary growth engine, with double-digit growth in 2025 and resilient hospital segments.

• China and emerging markets remain long-term opportunities, with a focus on innovation and local relevance.

Financial guidance and capital allocation

• Cumulative free cash flow of €4.5–5 billion targeted for 2026–2028, with leverage ratio to decline from 3.0x to 1.5–2.0x and organic ROIC rising to mid-teens.

• Margin expansion to be driven by growth, innovation, productivity, and a €1.5 billion productivity program over three years.

• Capital allocation priorities: organic growth (R&D, CapEx), stable dividend (40–50% payout), selective M&A, and opportunistic share buybacks.

• Segment-specific strategies underpin financial targets, with all businesses expected to contribute to sales and margin improvement.

• Tariff mitigation and regionalization investments, especially in North America, to offset external headwinds.

Innovation and business developments

• Accelerated innovation pipeline with world-first launches in imaging (helium-free 3T MRI, CT 5300), AI-native interventional platforms, and new monitoring platforms.

• Multi-year innovation roadmap prioritizes fewer, bigger, and better innovations, with R&D spend at 9% of sales and >60% anticipated sales increase from top-10 NPIs.

• Image-Guided Therapy and Precision Diagnosis positioned as growth engines, leveraging platform integration, AI, and strategic acquisitions.

• Connected Care focuses on expanding monitoring, cloud-based informatics, and preparing for re-entry into the U.S. Sleep & Respiratory Care market.

• Partnerships with leading clinical, technical, and cloud partners (e.g., Mayo Clinic, AWS, NVIDIA) to accelerate innovation and impact.